[Edaily Reporter Kim Seung-kwon] #CoreLineSoft is reaching a turning point where it will expand beyond simple image interpretation assistance into the digital biomarker business. This is because CoreLineSoft has secured AI-based quantitative analysis technology that enables long-term follow-up of patients with pulmonary fibrosis.

CoreLineSoft has not stopped at simply advancing its technology; in the first quarter of this year, it also achieved the milestone of securing a leading position in the operation of national screening infrastructure by signing new contracts with 11 top-tier medical institutions, including Charité in Germany. This is expected to mark a turning point in restructuring its revenue model, moving away from the existing one-time software sales model toward subscription-based (SaaS) and pay-per-use models aligned with national screening cycles.

CoreLineSoft’s AI diagnostic software now enables clinical trial follow-up

Interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF) are considered representative intractable diseases in clinical practice

,

where early diagnosis and long-term follow-up are directly linked to patient survival rates. This is because once fibrosis—the inflammation and hardening of the lung interstitium—progresses, there are limited treatments available to fundamentally reverse it. Until now, medical professionals have largely relied on decreases in forced vital capacity (FVC) and visual interpretations by specialists to assess disease progression. However, this approach had critical limitations, including significant variability between interpreters and test results that fluctuated depending on patient cooperation.

CoreLineSoft has directly overcome the limitations of this existing medical evaluation system through its interstitial lung disease analysis solution, AVIEW Lung Texture. A research team from the Department of Radiology and the Department of Pulmonology at Asan Medical Center in Seoul has demonstrated the clinical validity of the Fibrosis Score (FS) calculated using CoreLine Soft’s chest AI platform, AVIEW, and proposed a new candidate digital biomarker for predicting the prognosis of patients with interstitial lung disease (ILD). A key feature of this approach is that it quantifies structural changes that are difficult to detect through visual interpretation or pulmonary function tests (PFTs) alone. The research findings were published in the May 2026 issue of the world-renowned respiratory medicine journal *CHEST*, drawing significant attention from the global academic community.

The FS, calculated based on reticular and honeycomb opacities analyzed by AI in chest computed tomography (CT) images, is considered an indicator that quantifies key imaging patterns suggesting the progression of pulmonary fibrosis. Results from a one-year follow-up showed that changes in the FS demonstrated overwhelmingly higher statistical significance in assessing disease progression compared to the conventional clinical standard indicator, FVC decline. This means that AI can precisely quantify subtle structural deterioration even before overt lung function decline occurs, enabling proactive intervention.

It is suggested that this quantitative analysis technology could become a game-changer that fundamentally transforms the clinical trial environment for new drug development at global pharmaceutical companies. In clinical trials for new pulmonary fibrosis drugs, imaging data captured on different equipment across countries and hospitals must be analyzed using the same standards.

CoreLineSoft’s quantitative analysis solution maximizes data reproducibility by applying AI-based quantitative indices (cLAA and cHAA) that correct for errors caused by differences in imaging equipment or environments. This represents a unique competitive advantage, as the company has successfully integrated its solution into the objective patient screening and drug efficacy verification processes essential for multinational clinical trials.

A CoreLineSoft representative explained, “Through joint research with Asan Medical Center in Seoul, we have confirmed that eView Lung Texture is expanding into the field of digital biomarkers for evaluating the progression and prognosis of lung diseases.”

Technological Leap... Prospects for Future Technology Utilization

There are also projections that CoreLineSoft’s digital biomarker capabilities, proven in Korea, could directly contribute to a transformation of the company’s revenue structure. CoreLineSoft participated in the national lung cancer screening program with its low-dose CT-based lung cancer screening solution, AVIEW LCS, and established an on-premises model within hospitals. However, as the analysis of multiple diseases—such as pulmonary fibrosis, chronic obstructive pulmonary disease (COPD), and cardiovascular disease—is combined with long-term follow-up, the platform is evolving into an operational AI platform based on subscription and pay-per-use models.

Notably, in the first quarter of this year, CoreLine Soft signed new contracts with 11 top-tier medical institutions in Germany, including Charité Hospital, which is the largest and most prestigious in Europe.

Its activities in the United States, the world’s largest healthcare market, are also noteworthy. With support from the Inter-Ministerial Advanced Medical Device R&D Project, CoreLine Soft is pursuing U.S. Food and Drug Administration (FDA) 510(k) clearance and global commercialization.

Another key development is the recent introduction by the U.S. Centers for Medicare & Medicaid Services (CMS) of a new code (G0680) recognizing AI-based analysis of chest CT scans as a separate medical service. This is expected to further strengthen CoreLineSoft’s “Multi-disease Analysis” strategy, which simultaneously analyzes lung cancer, COPD, and cardiovascular risk in a single scan.

The proportion of overseas revenue and subscription revenue is also rebounding. Pay-per-use (PPU) revenue surged by approximately 320% year-over-year, demonstrating the pace of the transition to a SaaS model. Overseas revenue also surpassed 60% for the first time, reaching 62.4%, leading to analysis that the company is shifting from domestic-centric growth to growth driven by global demand.

A CoreLineSoft official stated, “While our lung cancer screening AI opened the door to national screening programs and hospital adoption, we believe our quantitative analysis technology for pulmonary fibrosis has demonstrated the potential to expand into a data-driven platform connected to the pharmaceutical and biotech industries.” The official added, “We expect CoreLineSoft to evolve beyond being a lung cancer screening AI company into a data platform company specializing in thoracic diseases.”